Small Patients, Big Risk: Pediatric MASLD
Early Identification and Thoughtful Management of a Complex Disease
|
Pediatric metabolic dysfunction-associated steatotic liver disease (MASLD) is often misunderstood and underdiagnosed. While many children with MASLD appear healthy, significant steatosis and fibrosis may already be present. In this white paper, pediatric hepatologist Dr. Alisha Mavis shares practical guidance for recognizing pediatric MASLD earlier, stratifying risk, and using FibroScan® to support thoughtful, longitudinal care. |
 |
Key learnings
Pediatric MASLD Is Different
Understand how pediatric MASLD differs from adult disease, including unique risk factors, developmental considerations, and long-term metabolic implications.
What Should Actually Raise Concern
Learn the clinical, metabolic, familial, and early-life risk factors Dr. Mavis uses to identify children who may warrant closer evaluation and follow-up.
Practical Thresholds for Clinical Decision-Making
Gain guidance on pediatric-specific ALT thresholds, FibroScan® interpretation, and the real-world framework Dr. Mavis uses to stratify risk, identify children who may need closer evaluation, and guide longitudinal management.
Integrating FibroScan® into Pediatric Care
Learn how FibroScan® supports early identification, risk assessment, monitoring, and more meaningful conversations with families.
Building a Longitudinal Care Strategy
Explore how tracking liver health over time can help providers monitor metabolic disease trajectory, support lifestyle interventions, and improve transitions into adult care.
Download the white paper to learn how earlier recognition of MASLD, thoughtful risk stratification, and non-invasive assessment with FibroScan® can support more informed metabolic care for children.
